Bausch Health shares are trading lower. The stock fell after an article suggested the company was considering bankruptcy but the company said it has not been involved in discussions with its creditors regarding bankruptcy proceedings.

7/24/24 3:05:24 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BHC alert in real time by email

Get the next $BHC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BHC

Date	Price Target	Rating	Analyst
8/2/2024	$9.00 → $3.00	Neutral → Underweight	Piper Sandler
7/10/2024	$8.00	Mkt Perform	Raymond James
9/20/2023	$9.00 → $16.00	Hold → Buy	Jefferies
6/16/2023		Outperform → Market Perform	TD Cowen
7/29/2022		Buy → Hold	Truist
7/29/2022	$12.00 → $5.00	Outperform → Sector Perform	RBC Capital Mkts
7/28/2022		Overweight → Neutral	JP Morgan
6/13/2022	$12.00	Overweight	JP Morgan

More analyst ratings

$BHC
Press Releases

Fastest customizable press release news feed in the world

Bausch Health Announces Third Quarter 2024 Results
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro
10/30/24 4:05:00 PM ET
$BHC
$NHC
Biotechnology: Pharmaceutical Preparations
Health Care
Hospital/Nursing Management
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology® 2024 Annual Scientific Meeting taking place October 25-30 in Philadelphia, PA. This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) re
10/27/24 12:15:00 PM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t
10/9/24 4:05:00 PM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care

$BHC
Financials

Live finance-specific insights

Bausch Health Announces Third Quarter 2024 Results
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro
10/30/24 4:05:00 PM ET
$BHC
$NHC
Biotechnology: Pharmaceutical Preparations
Health Care
Hospital/Nursing Management
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t
10/9/24 4:05:00 PM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care
Bausch Health Announces Second Quarter 2024 Results
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth
7/31/24 12:00:00 AM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care

Bausch Health Welcomes Two New Members to the Executive Leadership Team
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm
7/19/24 7:00:00 AM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing
12/5/23 8:00:00 AM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum DiseaseCollaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex RodriguezLAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community.Gum disease, also known as periodont
9/21/23 8:00:00 AM ET
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care

Bausch Health shares are trading lower. The stock fell after an article suggested the company was considering bankruptcy but the company said it has not been involved in discussions with its creditors regarding bankruptcy proceedings.

Chat with this insight

Recent Analyst Ratings for $BHC

$BHC Press Releases

Fastest customizable press release news feed in the world

Bausch Health Announces Third Quarter 2024 Results

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

$BHC SEC Filings

Bausch Health Companies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form SD filed by Bausch Health Companies Inc.

$BHC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Bausch Health downgraded by Piper Sandler with a new price target

Raymond James initiated coverage on Bausch Health with a new price target

Bausch Health upgraded by Jefferies with a new price target

$BHC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Wechsler Amy B was granted 842 shares, increasing direct ownership by 0.41% to 207,094 units (SEC Form 4)

Director Icahn Brett was granted 4,059 shares, increasing direct ownership by 3% to 152,671 units (SEC Form 4)

Director Paulson John was granted 7,659 shares, increasing direct ownership by 3% to 260,295 units (SEC Form 4)

$BHC Market Insights

Live Market Insights

Truist Securities Maintains Hold on Bausch Health Companies, Lowers Price Target to $7

Why Bausch health Shares Are Falling Today

Bausch Health shares are trading lower. The stock fell after an article suggested the company was considering bankruptcy but the company said it has not been involved in discussions with its creditors regarding bankruptcy proceedings.

$BHC Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Bausch Health Companies Inc.

Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

$BHC Financials

Live finance-specific insights

Bausch Health Announces Third Quarter 2024 Results

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Bausch Health Announces Second Quarter 2024 Results

$BHC Leadership Updates

Live Leadership Updates

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

Recent Analyst Ratings for
$BHC

$BHC
Press Releases

$BHC
SEC Filings

$BHC
Analyst Ratings

$BHC
Insider Trading

$BHC
Market Insights

$BHC
Large Ownership Changes

$BHC
Financials

$BHC
Leadership Updates